DiaMedica Therapeutics Inc. (NASDAQ:ONCT) major shareholder Pharmaceutical (Usa) Shanghai bought 1,049,317 shares of DiaMedica Therapeutics stock in a transaction dated Tuesday, July 21st. The stock was purchased at an average price of $2.38 per share, with a total value of $2,497,374.46. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of ONCT opened at $2.90 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.26 and a quick ratio of 2.26. The stock has a market capitalization of $44.63 million, a PE ratio of -0.68 and a beta of 1.38. DiaMedica Therapeutics Inc. has a one year low of $2.11 and a one year high of $6.29.
DiaMedica Therapeutics (NASDAQ:ONCT) last issued its earnings results on Thursday, May 7th. The company reported ($0.31) EPS for the quarter. The firm had revenue of $0.58 million during the quarter. DiaMedica Therapeutics had a negative net margin of 1,446.19% and a negative return on equity of 135.83%.
Oncternal Therapeutics, Inc, a clinical-stage biotechnology company, develops various product candidates for the treatment of cancer. The company's product pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is being evaluated in a Phase I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma; and TK-216, a small-molecule compound that is designed to inhibit E26 transformation-specific oncogene-family oncoproteins, which is being evaluated in a Phase I clinical trial alone and in combination with vincristine to treat Ewing sarcoma, a rare pediatric cancer.
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.